Gilead : U.S. FDA Approves Kite’s Tecartus® as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
— 65% of Patients Achieved Overall Complete Remission with Tecartus — — High Unmet Need: Fifty Percent of Adult Patients Will Relapse…